Reliefband® Technologies is a world-leader in neuromodulation (the alteration of nerve activity through targeted delivery of a stimulus to specific neurological sites in the body) and wearable technology. We build hardware products and software platforms powered by proven science, objective data, and clinical research for the treatment of nausea, retching and vomiting.Using highly effective and responsive technology, our digital wearable devices are clinically tested, FDA cleared and endorsed by the medical profession. Easy-to-use, comfortable and adjustable, they bring a life changing approach to treatment so that people can literally live their life in full motion again!
Wilbur is the Executive Chairman of Naurex, Inc., a biopharmaceutical company, and the President of PathoCapital LLC, a private investment firm. Mr. Gantz was formerly Chairman and Chief Executive Officer of Ovation Pharmaceuticals, Inc., a position assumed in 2002. Previously he served as Chairman and Chief Executive Officer of PathoGenesis Corporation and as President of Baxter International Inc. Mr. Gantz serves as a director of Adams Street Partners and is a trustee of the Field Museum.
David is the Founder, President and Chief Executive Officer of JVC Investment Partners LLC, since October 2000, a firm that provides private investment and strategic support to early stage and middle market businesses in the healthcare space. Mr. Jonas founded PHC in 2003 and was its Chairman and Chief Executive Officer until January 2014 and continue to be a member of its board of directors. Prior to founding JVC Investment Partners and PharMEDium, Mr. Jonas held a number of senior management position with Baxter including the co-founder and COO/CFO of Renal Therapy Services Worldwide Inc. a subsidiary of Baxter International Inc. Mr. Jonas served on boards of various privately held companies and non-for-profit organizations including the Chicago Medical School, Gore-Bronson Bancorp, Healthcare Venture Fund, Medica Venture Fund, IBAX Healthcare Systems. Mr Jonas received BS degree in Finance and MBA from Roosevelt University. Mr. Jonas business management experience, spanning more than 35 years, includes extensive strategic and operational experience in product development, manufacturing, sales and distribution of critical healthcare products and services.
Cameron is an accomplished pharmaceuticals and biotech entrepreneur, marketer, financing, business and corporate development professional with a strong medical base. He has served as chairman and director on the boards of numerous companies, and operated as CEO or interim CEO for four venture-backed companies. In other assignments, he has been a senior executive at Johnson and Johnson, Pharmacia Corporation, GSK and Merck,. He has served as the founding investor, Chairman and CEO of publicly-traded PediaRX (acquired by Apricus Biosciences, a NASDAQ company), Executive Chairman of publicly traded Anavez, CEO of PediaMed Pharmaceuticals (acquired by Connetics Corporation and also Tiber Labs), Chairman of Pressure Point (now with an FDA-cleared, marketed medical device), founding director of Bexion Pharmaceuticals (now with a Phase I, novel lipid/protein nanotech oncology therapeutic/imaging agent), board member of Topaz Pharmaceuticals (acquired by Sanofi-Pasteur), board member of PDS Biotechnology Corporation and founder investor in Prism Pharmaceuticals (acquired by Baxter). He has been involved in 5 exits, ranging from a 2-9x return. Dr. Durrant has been an advisor to Microsoft Corporation, Aprecia Pharmaceuticals, Pilgrim Software (acquired by a private equity group), PathXL and Saxa Private Equity Partners. He has also been involved in creating companies around targeted early-stage technologies with Cincinnati Children’s Hospital and assisted numerous private equity groups in their diligence efforts, leading to successful deal closure. He has raised significant capital in VC, private equity, angel and high net worth financings.
Bruce is the retired Chairman and CEO of Fortune Brands, the $7 billion consumer products company. Today, he invests and sits on boards of high potential startups and mid cap private equity companies who are focused on strategic growth. Bruce is also currently the Lead Director and Chairman of the Governance and Nominating committee of RPM International, Inc. During his 20 plus years at Fortune Brands, Bruce held many leadership positions starting with being President and CEO of Moen in 1989. Under his leadership, Moen more the quadrupled it sales to over $1 billion dollars and became the number one brand in the North America and the most profitable business within Fortune Brands. By 2000, he was the President and CEO of the Fortune Brands Home and Security Business that more than doubled to over $4 billion in sales. Being promoted to President and COO of Fortune Brands in 2005, he led the 5-year transformation of the spirits business from an underperforming business unit to becoming the fastest growing spirits business in the world. And finally under his chairmanship at Fortune Brands, he lead the split up of Fortune Brands creating significant shareholder value. Prior to joining Fortune Brands, he held positions at Forstmann Little, Stanadyne and Price Waterhouse. Bruce has been honored and inducted into numerous business hall of fames and currently involved in numerous leadership position in non-profit organizations.
Christopher is currently Co-Founder and Chief Executive Officer of ParaBellum Partners, LLC. The company was founded in 2017 with the intent of developing products for both Direct to Consumer and Retail channels. Prior to ParaBellum Partners, LLC, Chris was the President and CEO for Ducere Pharma, LLC from 2014 to 2016. Upon his arrival, he was tasked with revitalizing iconic brands like Doan’s, Bufferin, and Cruex. Within 2 years Doan’s became #1 SKU in the back-pain set. During his tenure, Ducere increased distribution to more than 40,000 outlets across all brands and the company was sold with a 3X ROI for investors. From 2008 to 2013, Chris was the President and CEO of Ultimark Products where his business strategies increased revenue for the Ultimark’s garden division by 200%. While at Ultimark, Chris raised over $15.0M in a Private Placement to further the business’s acquisition goals. Chris Dominello’ s career also includes eight years at NutriSystem Inc. in numerous capacities including Director of Operations and President of the company's exercise franchise division. During his time at NutriSytem, Chris’s marketing strategies were documented in Business Week magazine and The Wall Street Journal. During his tenure, NutriSystem revenues increased by over 3700% from $20.0M to $777.0M. Chris is a graduate of the University of Notre Dame's Mendoza College of Business with a Bachelor of Science in Accounting. He was also an Officer in the United States Air Force and received the Meritorious Service Medal.
Jeffrey is a partner of the law firm of Fox Rothschild LLP and Chair of the Firm’s Corporate Department, focuses his practice on capital formation, public company reporting, compliance and transactions, corporate governance, and M&A. This includes working with Boards of Directors and entrepreneurs at each point in the life cycle of business formation, growth and exit transactions. Jeff serves many clients as general counsel where he combines his broad legal experience with a practical business sense. Jeff is a member of Fox Rothschild’s Executive Committee and is managing partner of the firm’s 30 lawyer Bucks County office. Jeff serves as managing director of Delaware Crossing Investor Group (www.delawarecrossing.org), an angel investor network conceived of and managed with two Fox Rothschild colleagues. Jeff is a member of the Executive Committee of Heritage Conservancy, a leading regional land preservation group. He is also active in Fisherman’s Mark, a not-for-profit which provides assistance to the needy in the Lawrenceville, NJ area. Jeff has served in a number of other leadership roles at Fox Rothschild, including Chair of the Emerging Companies Practice Group and Chair of Public Companies Practice Group.
Keith Terry is a business and leadership expert with more than 25 years of global business experience. Over his professional career, Keith has served as President & CEO of TPG, Inc., Vice President of Marketing and Account Management of AHA Solutions, Inc., and Executive Director of the Chicago Innovation Mentors (a health technology incubator and collaboration between University of Chicago, Northwestern, University of Illinois, and IBIO). , He was also a Co-Founder & Senior Vice President at Ocularis Pharma, Inc., General Manager of International for PathoGenesis Corporation, Strategic Marketing Director for the HUMIRA Franchise at Abbott Labs (now AbbVie), and has held various leadership positions at other companies including Chiron and Upjohn. Keith is a Certified High-Performance Leadership Development expert and is also a two-time Review Panelist for the National Science Foundation. Keith has enjoyed phenomenal success in growing bottom line results by building and innovating global brands.
Gene Godick has over 25 years of financial and executive experience including eight years of Big Five public accounting experience. Most recently, Gene founded G-Squared Partners, LLC a company that is providing CFO services as well as financial and operational consulting to many of the leading venture backed and technology companies in the NY to DC corridor. Gene led the Verticalnet IPO, where the company raised $64 million in equity. During his tenure at Verticalnet, he raised over $300 million and completed over 25 M&A transactions.
Bob Verdugo is a seasoned commercial executive in healthcare as well as prescription and OTC consumer product businesses, Bob Verdugo is highly skilled in commercial marketing, sales planning, supply chain, and new product planning in regulated, medical and retail environments. With over 30 years leading business growth in the US & Internationally, Bob has held positions of increasing responsibility in public, private and venture backed organizations including Sanofi Topaz Pharmaceuticals, Merck & Co. Inc. Merial Ltd. and Zoetis. Bob is also the founder and principal of Xtra Marketing Resource LLC, a firm specializing in marketing planning and consulting.
Randy Mitch is an operations and supply chain executive with over 25 years of experience in delivering operational improvement in supply chain efficiencies and strategic source planning. As Chief Supply Chain Officer at Drive Medical Design and Manufacturing, Randy improved supply chain efficiencies by over 33% and increased inventory turns by 35%, reducing on hand inventory requirements by $16M. Prior to joining Drive Medical, Randy served as Senior VP of Supply Chain and Operations at Altec Lansing and VP of Operations at Philips Accessories.